Colorectal Cancer
Conditions
Keywords
retina, OCT-angiography, Anti-VEGF, microvascularization, Targeted therapy
Brief summary
Retinal microvascularization can provide important informations to systemic vascular phenomena. The non-invasive quantitative description of the retinal vascularization is now possible by performing OCT-angiography and their image analysis software (vascular density and retinal perfusion). Systemic microvacular changes during the establishment of oncological treatment by targeted antiangiogenic therapy are little described in the literature. The objective of this pilot study is to describe the evolution of the retinal vascular density of patients with antiangiogenic drugs. In addition, the evolution of the retinal vascular density of patients on antiangiogenic drugs will study as a function of the response to the treatment and the toxicity of these treatments.
Detailed description
The main objective of this study is to describe the change in retinal vascular density of patients with first-line colorectal cancer treated with Bevacizumab.
Interventions
OTHEROCT- Angiographie
Ophthalmological examinations
Sponsors
Centre Georges Francois Leclerc
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patient over 18 years old starting first-line treatment for metastatic colorectal cancer including BEVACIZUMAB (AVASTIN®) 2. Systemic or intraocular anti-VEGF treatment naïve 3. ECOG ≤ 2
Exclusion criteria
1. Pregnant woman, 2. Minor patient or under legal protection 3. Person deprived of liberty or under guardianship 4. Inability to undergo medical monitoring of the trial 5. Impossibility of carrying out the OCT-A 6. Patient with a contraindication to Tropicamide 0.5% eye drops 7. Patient with a history of degenerative macular pathology, vascular macular pathology or presenting an epiretinal membrane with traction phenomenon. 8. Diabetes 9. Patient for whom it is not possible to schedule an ophthalmology consultation before the start of treatment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| retinal vascular density retinal vascular density | 12 month | this measurement will be the average of the 4 quadrants (temporal, nasal, superior and inferior 24). It will be performed by PLEX Elite 9000 Swept Source OCT-A before, during and at the end of the anti-angiogenic treatment |
Countries
France
Contacts
Primary ContactAudrey HENNEQUIN
Outcome results
None listed